As such, inhibition of TGF-β signaling, with TGF-β type I receptor kinase inhibitors, attenuates metastasis after paclitaxel therapy and enhances the anti-tumor effect of this chemotherapeutic [17, 18]. Here, TGFB1 is linked to neoplasm.